Inactive Instrument
Claritas Pharmaceuticals Share Price Toronto S.E.
Stocks
KLY
CA1806341071
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 53.68L 38.08L 33.41L 31.03L 28.51L 37Cr 54.53L 3.7Cr 1.44Cr 18Cr 1.43Cr 1.4Cr 62Cr | P/E 2019 |
-0.74x | P/E 2020 | 0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 62.88L 44.6L 39.13L 36.35L 33.39L 43Cr 63.87L 4.33Cr 1.69Cr 21Cr 1.68Cr 1.64Cr 73Cr | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
99.74% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 day | +11.11% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CEO | Chief Executive Officer | 76 | 21/06/2017 |
Victoria Rudman
DFI | Director of Finance/CFO | 58 | 29/06/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CHM | Chairman | 76 | 18/03/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +11.11% | -.--% | - | - | 37 | |
| -4.89% | -7.90% | -4.49% | +9.27% | 4.85TCr | |
| -0.14% | -1.05% | +376.39% | +583.71% | 3.9TCr | |
| +0.39% | +4.36% | +9.59% | +61.99% | 3.54TCr | |
| -1.54% | -4.48% | +24.89% | -13.03% | 3.37TCr | |
| -0.87% | -1.56% | -1.43% | +29.16% | 2.66TCr | |
| -1.28% | -5.14% | - | - | 1.68TCr | |
| -0.67% | -1.50% | +70.98% | +115.31% | 1.52TCr | |
| +1.32% | +2.29% | +14.62% | +15.52% | 1.39TCr | |
| +0.40% | -0.41% | +19.80% | -31.98% | 1.28TCr | |
| Average | +2.19% | -1.21% | +63.79% | +96.24% | 2.69TCr | |
| Weighted average by Cap. | -0.16% | -1.28% | +76.11% | +121.29% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -2.12Cr -1.5Cr -1.32Cr -1.23Cr -1.13Cr -145.39Cr -2.15Cr -15Cr -5.7Cr -71Cr -5.65Cr -5.53Cr -245.47Cr | 42.1L 29.86L 26.2L 24.34L 22.35L 29Cr 42.76L 2.9Cr 1.13Cr 14Cr 1.12Cr 1.1Cr 49Cr |
| Net Debt | 7L 5L 4L 4L 4L 4.83Cr 7L 48.46L 18.92L 2.36Cr 18.76L 18.36L 8.15Cr | 9L 7L 6L 5L 5L 6.31Cr 9L 63.33L 24.73L 3.08Cr 24.52L 23.99L 11Cr |
Employees
-
